GlaxoSmithKline expects to settle 1,000 more cases in addition to the 12,000 it has settled over the past eight months related to its diabetes drug, Avandia, which was once the world’s best-selling diabetes pill and generated $3 billion in annual sales.
Former Avandia patients have sued the drugmaker in state courts in Pennsylvania, California and Illinois alleging that the company failed to warn Avandia patients that the drug could cause heart attacks and strokes.
In September, the company announced it would stop promoting Avandia worldwide after regulators said the treatment would be withdrawn from the market in Europe and sales would be limited in the U.S. because of studies linking the drug to increased risks of heart attacks. After the restriction, sales of Avandia fell 43 percent.
In addition to approximately 5,300 state court cases, Glaxo faces about 1,600 suits that were consolidated before a U.S. District judge in Philadelphia.
The attorneys at Messa & Associates are experienced at handling cases involving pharmaceutical and drug product injuries. Our skilled team of attorneys has successfully pursued litigation and obtained verdicts and settlements for victims of pharmaceutical injuries. If you or a loved one is has suffered serious injuries as a result of taking the diabetes drug Avandia, please contact us at 1-877-MessaLaw.
No comments:
Post a Comment